It has never completed human clinical trials, so nobody can honestly answer that with trial data. What exists: controlled animal work (including human scalp follicles grafted onto testosterone-conditioned mice, where RU-58841 improved regrowth) and two decades of community use with a large body of anecdotal photographic reports. That is meaningful signal, but it is not proof, and its efficacy in humans has never been formally established.

How does RU58841 work?

It is a nonsteroidal androgen receptor antagonist. Applied topically, it competes with dihydrotestosterone (DHT) for the androgen receptor inside scalp follicles. If DHT cannot bind the receptor, it cannot drive the gene expression that miniaturises the follicle. Unlike finasteride, it does not lower DHT levels. It blocks DHT's effect locally.

Does RU58841 go systemic?

Unknown in humans. No human pharmacokinetic data has ever been published. The 1990s animal work reported topical antiandrogen activity with limited systemic effect, which is why the molecule attracted interest. Community reports at heavier use include systemic-feeling effects, and absorption will vary with dose, vehicle and skin condition. Treat systemic exposure as an unquantified variable, not a solved one.

Does RU58841 cause shedding?

An early shed in the first weeks is commonly reported anecdotally. Mechanistically it is plausible: treatments that push follicles back toward the growth (anagen) phase can first release club hairs from the resting phase. But it has never been documented in a controlled human study, because none exist.

How long does RU58841 take to work?

There is no trial-established timeline. Community reports typically describe judging stabilisation over months, not weeks, which matches the biology: a hair cycle turns over slowly, so any real change in miniaturisation takes months to become visible. Anyone promising a specific week-count is inventing it.

Should I buy RU58841 powder or a pre-made solution?

Powder is cheaper per gram but puts formulation on you: accurate weighing, a suitable vehicle, and purity you can only confirm with your own lab test. A properly made solution should state its actual assayed concentration, not just the powder's purity. Ours is quantitatively assayed by an independent lab per batch. Batch 30582 assayed 55.08 mg/mL against its 50 mg/mL label.

Why are there crystals in my RU58841 solution?

At 5% (50 mg/mL), RU-58841 sits near its solubility ceiling in ethanol-based vehicles. In the cold it can crystallise out. That is physics, not degradation. Gentle warming and agitation re-dissolves it. Store cool but not frozen, in the dark.

Is RU58841 legal in the UK?

RU-58841 is not a controlled drug in the UK, and it is not a licensed medicine. Norwood Labs sells it strictly as a reference material for laboratory research use, and makes no medical or treatment claims.

What Is RU58841 (RU-58841)? A Research Overview (2026)

The short version

RU-58841 is a nonsteroidal androgen receptor antagonist from the same chemical family as nilutamide, developed by Roussel-Uclaf in the 1980s.
Applied topically, it blocks DHT at the follicle's androgen receptor. It does not lower DHT anywhere.
The evidence is animal studies plus 20+ years of community use. It never completed human trials.
Quality varies wildly between vendors; the only defence is a real, verifiable, batch-specific CoA.
Not a licensed medicine. Research use only. Nothing here is dosing or treatment advice.

What RU58841 actually is

RU-58841 (also written RU58841, and later carried under the codes PSK-3841 and HMR-3841) is a small-molecule nonsteroidal androgen receptor antagonist. Chemically it is a phenylhydantoin: the same 4-cyano-3-(trifluoromethyl)phenyl "warhead" you find in the prostate-cancer antiandrogens nilutamide and bicalutamide, attached to a hydantoin ring with a hydroxybutyl tail. That aryl group is what the androgen receptor grabs; the rest of the molecule was tuned for one job: working through skin, locally.

It was developed by Roussel-Uclaf in France in the late 1980s as a topical treatment for acne, hirsutism and androgenetic alopecia, conditions driven by androgens acting locally in skin, where a systemic antiandrogen would be the wrong tool. The company's own pharmacologists described the design goal openly: strong androgen receptor blockade at the application site, minimal antiandrogenic effect elsewhere.

How it works

Pattern hair loss is driven by dihydrotestosterone (DHT) binding the androgen receptor (AR) inside genetically susceptible follicles. The DHT-AR complex moves to the nucleus and switches on a gene programme that progressively shrinks the follicle: thinner shafts, shorter growth phases, and eventually a follicle too small to produce visible hair.

RU-58841 is a competitive AR antagonist: it occupies the receptor's binding pocket without activating it. DHT that cannot dock cannot signal. The important contrast is with finasteride and dutasteride, which inhibit 5α-reductase and lower DHT production across the whole body. RU-58841 leaves your hormone levels untouched and instead blocks the receptor at the point of application. Same pathway, opposite end, which is also why the two approaches are mechanistically complementary rather than redundant, and why blockading the receptor works downstream of any amount of circulating DHT.

The evidence that exists

Be suspicious of any page that either dismisses RU-58841 outright or talks about it like an approved drug. The real evidence base is narrow but not empty:

Battmann et al., 1994 (J Steroid Biochem Mol Biol): the original pharmacology paper. In rodent models, topical RU-58841 produced strong local antiandrogenic effects with little systemic antiandrogenic activity, the "topical action" profile that defines the molecule.
De Brouwer et al., 1997 (Br J Dermatol, PMID 9415227): human scalp follicles from balding donors were grafted onto testosterone-conditioned nude mice; RU-58841 treatment improved regrowth parameters versus control. Human tissue, controlled design, but still a mouse, not a person.
Stump-tailed macaque work (late 1990s): the macaque is the classic animal model of androgenetic alopecia, and controlled topical RU-58841 studies in it reported follicular enlargement and regrowth.
The community record: twenty-plus years of self-experimentation across forums like r/tressless, with a large body of photographic before/after reports. Anecdote, selection-biased, uncontrolled, and still the largest single source of human signal that exists for this molecule.

Why it never became a drug

Roussel-Uclaf was folded through a chain of mergers (into Hoechst Marion Roussel, then Aventis), and RU-58841 passed to smaller companies under the PSK-3841 name. Early-phase human studies were reported only in company materials and conference notes; full results were never published, and development quietly stopped in the mid-2000s. The consistent read is that the programme died for commercial reasons (patent runway, corporate churn, and a crowded market) rather than a published safety failure. But the practical consequence is the same either way: no completed trials, no established human safety profile, no approval anywhere. That is exactly why it exists only as a research compound, and why nobody selling it may lawfully claim it treats anything.

The practical chemistry: vehicles, solubility, stability

Three physical facts about RU-58841 explain most of what you see in practice:

It sits near saturation at 5%. RU-58841's solubility in ethanol is around the 30-50 mg/mL region, so a 50 mg/mL solution is close to the ceiling. Good formulations use an ethanol/propylene-glycol co-solvent (ours is 70/30 ethanol/PG) and full dissolution takes deliberate work. This is also why cheap, rushed formulations underdose.
Cold makes crystals. Near-saturated solutions can crystallise in the cold. It re-dissolves with gentle warming; it is not degradation.
Light is the enemy. The molecule is photosensitive, which is why it belongs in amber UV-attenuating glass, stored cool and dark.

The quality problem, and how to not get burned

RU-58841 has no licensed supply chain, so quality is whatever the vendor decides it is. The community's independent tests over the years have repeatedly caught underdosed or mislabelled product. There is exactly one defence: a batch-specific Certificate of Analysis you can verify with the lab that issued it and not a stock JPEG on a product page.

This is the standard we hold ourselves to. Our raw powder is assayed for purity before formulation, the weigh-in is corrected by that purity figure, and the finished solution is then quantitatively assayed for actual concentration. Batch 30582 assayed at 55.08 mg/mL against its 50 mg/mL label, released at or above label, never below, and you can read the certificate on the lab's own site from our lab results page or by scanning the QR on the bottle.

Shop

RU-58841 5% Solution

50 mg/mL, batch-assayed, CoA public.

View product →

Where it sits against the alternatives

Against finasteride: different mechanism (receptor blockade vs DHT suppression), no effect on serum hormone levels by design, no human trial record. Finasteride has decades of it. Against pyrilutamide (KX-826): same mechanism, but pyrilutamide has actual human trial data and a gentler reputation, while RU-58841 has the longer community record and the harder-hitting reputation. We compared them properly in RU-58841 vs Pyrilutamide, and covered what is reported to go wrong in RU58841 side effects: what the research actually shows.

The honest caveats

RU-58841 is not a licensed medicine anywhere in the world. It has never completed human clinical trials, its human safety profile is not established, and Norwood Labs makes no medical or treatment claims about it. Everything we sell is a reference material for laboratory research use, sold on its identity and assayed concentration, the two things we can actually prove.

What Is RU58841? A Research Overview